Editorial standards
Spectral Genomics covers medicine and investment-relevant information at the same time. Both demand accuracy, so these are the rules every page on this site follows.
Who writes our content
Articles and profiles are published by Spectral Genomics Editorial, the team responsible for this site. Our content is not currently reviewed by named outside experts, and we do not describe content as expert-reviewed unless it has been. If an article is reviewed by a named expert, the reviewer’s name and credentials appear on that article.
Our core rules
- Every scientific claim has a traceable source, listed on the page where the claim appears.
- Company-reported findings, such as press releases, investor presentations, and conference abstracts, are labeled separately from peer-reviewed findings.
- Every probability estimate discloses its method and its uncertainty.
- Every prediction carries a timestamp and a model version.
- Historical predictions remain available, including those that turned out to be wrong.
- Editorial content is independent of sponsors, advertisers, and the companies we cover.
- Financial relationships and conflicts of interest are disclosed.
- We never imply that an experimental drug is proven effective based on preliminary findings.
- We never present an approval probability as a recommendation to buy or sell securities.
How we rank sources
When sources disagree, or when we describe the strength of evidence, we weigh them in roughly this order:
| Source type | Examples | How we label it |
|---|---|---|
| Regulatory records | FDA approval letters, review documents, labels | Regulator |
| Peer-reviewed publications | Journal articles indexed in PubMed | Peer-reviewed |
| Trial registries | ClinicalTrials.gov, WHO ICTRP | Registry |
| Statutes and regulations | Code of Federal Regulations | Statute / regulation |
| Company disclosures | SEC filings, press releases, presentations | Company-reported |
| Industry analyses | Aggregate success-rate reports | Industry report |
A conference abstract or press release can be newsworthy, but it has not been through peer review, and its data may change when the full results are published. We say so whenever we cite one.
Words we use carefully
- “Effective” is reserved for drugs whose benefit has been shown in adequate, controlled trials, not for early or uncontrolled results.
- “Breakthrough” refers only to the FDA’s Breakthrough Therapy designation, never to describe results generally.
- “Safety signal” means a possible association that needs investigation. Adverse event reports, such as those in the FDA’s FAERS database, do not by themselves show that a drug caused an event.
Evergreen content and updates
Our educational articles are maintained as evergreen references rather than dated news posts. When new evidence or a regulatory change affects an article, we update it. Database records, such as trial statuses and regulatory events, carry the date they were retrieved from their source.
Corrections
If we get something wrong, we correct it and add a note to the affected page describing what changed. We never silently edit a published probability estimate. Changes to estimates are recorded in that drug’s estimate history.
Independence
Spectral Genomics does not accept payment for coverage, and companies cannot review or approve what we publish about them before publication. If we ever offer sponsored research, it will be clearly labeled and kept separate from our independent analysis and probability estimates.
See also: probability methodology · disclaimer